Since PAI-1 and tPA may involve in the transformation of proBDNF to mBDNF, tPA over-expression or a decrease in PAI-1 may present therapeutic effects for the treatment of depression especially for patients that have an abnormality in the tPA–plasmin pathway or comorbidities relating to cardiovascular disease. The gene discussed is PLG; the disease is depressive disorder.